NGM Biopharmaceuticals, Inc. Common Stock
NGM
NGM was delisted on the 4th of April, 2024.
106 hedge funds and large institutions have $124M invested in NGM Biopharmaceuticals, Inc. Common Stock in 2023 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 41 increasing their positions, 38 reducing their positions, and 27 closing their positions.
1,000% more call options, than puts
Call options by funds: $33K | Put options by funds: $3K
8% more repeat investments, than reductions
Existing positions increased: 41 | Existing positions reduced: 38
13% less funds holding
Funds holding: 122 → 106 (-16)
38% less capital invested
Capital invested by funds: $200M → $124M (-$76M)
59% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 27
67% less funds holding in top 10
Funds holding in top 10: 3 → 1 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$1.88M |
| 2 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$1.47M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$960K |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
+$715K |
| 5 |
State Street
Boston,
Massachusetts
|
+$418K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$3.16M |
| 2 |
Millennium Management
New York
|
-$1.95M |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$586K |
| 4 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
-$572K |
| 5 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$387K |
NGM Hedge Fund Activity: Q2 2023 in Review
106 of the 6,370 institutional investors tracked by Wall St. Rank reported a position in NGM Biopharmaceuticals, Inc. Common Stock (NGM) for Q2 2023, worth a combined $124M — down 38% from $200M a quarter earlier.
Sellers outnumbered buyers: 27 funds closed out of NGM and 11 opened new positions — a net loss of 16 holders — while 38 trimmed existing stakes and 41 added.
The largest buyer was BlackRock, adding an estimated $1.88M. The largest seller was Vanguard Group, cutting an estimated $3.16M.
- 106 institutional investors held NGM Biopharmaceuticals, Inc. Common Stock (NGM) as of Q2 2023, down from 122 in Q1 2023.
- Funds reported $124M of NGM Biopharmaceuticals, Inc. Common Stock stock for Q2 2023, down 38% quarter-over-quarter.
- 11 funds opened new NGM Biopharmaceuticals, Inc. Common Stock positions in Q2 2023 and 27 closed out, a net change of -16 holders.
- The largest NGM Biopharmaceuticals, Inc. Common Stock buyer in Q2 2023 was BlackRock, an estimated $1.88M added.
- The largest NGM Biopharmaceuticals, Inc. Common Stock seller in Q2 2023 was Vanguard Group, an estimated $3.16M sold.
Based on aggregated 13F filings for Q2 2023.